We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
-1.15%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$34.7M
AUM Growth
-$282M
(-89%)
Cap. Flow
-$261M
Cap. Flow
% of AUM
-752.45%
Top 10 Holdings %
Top 10 Hldgs %
75.76%
Holding
38
New
7
Increased
–
Reduced
18
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
+$1.91M |
| 2 |
Gilead Sciences
GILD
|
+$1.57M |
| 3 |
McKesson
MCK
|
+$1.1M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$538K |
| 5 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
+$347K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$24.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$17.7M |
| 3 |
Sanofi
SNY
|
+$17.1M |
| 4 |
Viatris
VTRS
|
+$16.1M |
| 5 |
Pfizer
PFE
|
+$15.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Miscellaneous | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Amgen
AMGN
$236B
| – | – |
-59,300
| Closed | -$10.1M |
|
27
Bristol-Myers Squibb
BMY
$136B
| – | – |
-81,600
| Closed | -$5.16M |
|
28
Cencora
COR
$63.2B
| – | – |
-57,600
| Closed | -$4.97M |
|
|
EXAS
29
PUT
DELISTED
Exact Sciences
EXAS
| – | – |
-541,900
| Closed | -$21.9M |
|
30
Ironwood Pharmaceuticals
IRWD
$704M
| – | – |
-775,890
| Closed | -$10M |
|
31
Medtronic
MDT
$121B
| – | – |
-159,850
| Closed | -$12.8M |
|
32
Novartis
NVS
$304B
| – | – |
-142,067
| Closed | -$10.3M |
|
|
33
Pfizer
PFE
$162B
| – | – |
-458,869
| Closed | -$15.5M |
|
34
Dr. Reddy's Laboratories
RDY
$9.97B
| – | – |
-1,475,660
| Closed | -$9.65M |
|
|
SIEN
35
DELISTED
Sientra, Inc.
SIEN
| – | – |
-52,921
| Closed | -$5.11M |
|
|
AERI
36
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-70,668
| Closed | -$3.83M |
|
|
NXTM
37
DELISTED
NxStage Medical Inc.
NXTM
| – | – |
-208,480
| Closed | -$5.18M |
|
|
AET
38
DELISTED
Aetna Inc
AET
| – | – |
-43,900
| Closed | -$7.42M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q2 2018 Portfolio in Review
As of Q2 2018, Senzar Asset Management held 38 positions worth $34.7M, down 89% from $317M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Senzar Asset Management withdrew a net $261M in Q2 2018, closing 13 positions and reducing 18 holdings. Its most notable exit was Pfizer, an estimated $15.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Senzar Asset Management opened a new position in Radius Health, Inc. worth $1.78M.
- Senzar Asset Management's largest Q2 2018 buy was Radius Health, Inc.: 60,521 shares worth $1.78M.
- Senzar Asset Management's biggest Q2 2018 reduction was AstraZeneca, cutting an estimated $24.7M.
- Senzar Asset Management fully exited Pfizer in Q2 2018, selling an estimated $15.5M.
- Senzar Asset Management's ten largest holdings make up 76% of its $34.7M portfolio in Q2 2018.
- Senzar Asset Management opened 7 new positions and closed 13 in Q2 2018.
- Senzar Asset Management's portfolio value fell 89% quarter-over-quarter to $34.7M.
Based on Senzar Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.